{"organizations": [], "uuid": "29785b1fab37642771711ba1e36881516580509a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/abbvie-study/abbvie-says-not-seeking-accelerated-approval-for-lung-cancer-drug-idUSL3N1R44OX", "country": "US", "domain_rank": 408, "title": "AbbVie says not seeking accelerated approval for lung cancer drug", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-22T14:57:00.000+02:00", "replies_count": 0, "uuid": "29785b1fab37642771711ba1e36881516580509a"}, "author": "", "url": "https://www.reuters.com/article/abbvie-study/abbvie-says-not-seeking-accelerated-approval-for-lung-cancer-drug-idUSL3N1R44OX", "ord_in_thread": 0, "title": "AbbVie says not seeking accelerated approval for lung cancer drug", "locations": [], "entities": {"persons": [{"name": "abbvie", "sentiment": "negative"}, {"name": "anil d’silva", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "abbvie", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 22, 2018 / 12:58 PM / Updated 9 minutes ago AbbVie says not seeking accelerated approval for lung cancer drug Reuters Staff 1 Min Read March 22 (Reuters) - Drugmaker AbbVie Inc said on Thursday it will not seek accelerated approval for its experimental lung cancer treatment based on results from a mid-stage study. The study was testing the company’s Rova-T as a treatment for patients with small cell lung cancer who did not respond to at least two prior regimens. Late-stage trials testing the drug as a treatment for patients in the earlier stages of the disease will continue, the company said. (Reporting by Tamara Mathias in Bengaluru; Editing by Anil D’Silva)", "external_links": [], "published": "2018-03-22T14:57:00.000+02:00", "crawled": "2018-03-22T15:15:40.009+02:00", "highlightTitle": ""}